The impact of antisense oligonucleotide (ASO) therapeutics on the future of rare disease drug discovery
Antisense drugs are expanding as tools for treating rare diseases, reflecting innovation in how genetic medicine approaches conditions with few options.
This editorial from UConn Pharmacy summarizes the growing role of antisense oligonucleotide (ASO) therapeutics in rare disease drug discovery, noting the expansion of FDA-approved ASOs and emerging nucleic acid chemistry platforms. As an editorial, it provides context rather than novel data.
What the study was
- Study design
- Editorial commentary
- Category
- Drug Development
- Maturity
- Exploratory
- Journal
- Expert Opinion on Drug Discovery
Why it surfaced
Editorial format; included per sparse rare disease topic exception rule (11 hits total in window). Score capped at 3 per editorial cap rule.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.